CY1120844T1 - Νεες ενωσεις πυρρολοπυριμιδινης ως αναστολεις των πρωτεϊνικων κινασων - Google Patents

Νεες ενωσεις πυρρολοπυριμιδινης ως αναστολεις των πρωτεϊνικων κινασων

Info

Publication number
CY1120844T1
CY1120844T1 CY171100274T CY171100274T CY1120844T1 CY 1120844 T1 CY1120844 T1 CY 1120844T1 CY 171100274 T CY171100274 T CY 171100274T CY 171100274 T CY171100274 T CY 171100274T CY 1120844 T1 CY1120844 T1 CY 1120844T1
Authority
CY
Cyprus
Prior art keywords
prohibitors
pyrolopyrimidine
movies
protein
compounds
Prior art date
Application number
CY171100274T
Other languages
English (en)
Inventor
Xiao Xu
Xiaobo Wang
Long Mao
Li Zhao
Biao Xi
Original Assignee
Acea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/843,554 external-priority patent/US9034885B2/en
Application filed by Acea Biosciences Inc filed Critical Acea Biosciences Inc
Publication of CY1120844T1 publication Critical patent/CY1120844T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ορισμένα παράγωγα πυρρολοπυριμιδίνης, φαρμακευτικές συνθέσεις που τα περιέχουν, και σε μεθόδους χρήσης αυτών, συμπεριλαμβανομένων μεθόδων για τη θεραπευτική αντιμετώπιση πολλαπλασιαστικών διαταραχών και άλλων παθήσεων που σχετίζονται με την απορρύθμιση της κινάσης (όπως, αλλά δεν περιορίζεται σε, EGFR (συμπεριλαμβανομένης της HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC και TXK) και/ή τις αντίστοιχες διαδρομές.
CY171100274T 2012-08-06 2017-03-02 Νεες ενωσεις πυρρολοπυριμιδινης ως αναστολεις των πρωτεϊνικων κινασων CY1120844T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261680231P 2012-08-06 2012-08-06
US13/843,554 US9034885B2 (en) 2012-01-13 2013-03-15 EGFR modulators and uses thereof
US201361814147P 2013-04-19 2013-04-19
US13/917,514 US8685988B2 (en) 2012-08-06 2013-06-13 EGFR modulators and uses thereof
PCT/US2013/050163 WO2014025486A1 (en) 2012-08-06 2013-07-11 Novel pyrrolopyrimidine compounds as inhibitors of protein kinases

Publications (1)

Publication Number Publication Date
CY1120844T1 true CY1120844T1 (el) 2019-12-11

Family

ID=50068479

Family Applications (1)

Application Number Title Priority Date Filing Date
CY171100274T CY1120844T1 (el) 2012-08-06 2017-03-02 Νεες ενωσεις πυρρολοπυριμιδινης ως αναστολεις των πρωτεϊνικων κινασων

Country Status (22)

Country Link
EP (2) EP2880035B9 (el)
JP (2) JP6215938B2 (el)
KR (1) KR102181365B1 (el)
CN (2) CN107266453B (el)
AU (1) AU2013300106B2 (el)
BR (1) BR112015002709B1 (el)
CA (1) CA2881275C (el)
CY (1) CY1120844T1 (el)
DK (1) DK2880035T3 (el)
ES (2) ES2618007T3 (el)
HK (1) HK1210471A1 (el)
HR (1) HRP20170311T1 (el)
HU (1) HUE031955T2 (el)
IN (1) IN2015DN00914A (el)
LT (1) LT2880035T (el)
MX (1) MX361992B (el)
NZ (1) NZ629807A (el)
PT (1) PT2880035T (el)
RU (2) RU2018104702A (el)
SG (1) SG11201500872SA (el)
WO (1) WO2014025486A1 (el)
ZA (2) ZA201500762B (el)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013013188A1 (en) 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
US10799504B2 (en) 2012-01-13 2020-10-13 ACEA Therapeutics, Inc. Heterocyclic compounds and uses as anticancer agents
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014151871A2 (en) * 2013-03-14 2014-09-25 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use
CN105916851A (zh) * 2013-07-11 2016-08-31 艾森生物科学公司 嘧啶衍生物作为激酶抑制剂
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
KR20170024120A (ko) 2014-07-14 2017-03-06 시그날 파마소티칼 엘엘씨 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물
CA2976109A1 (en) 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Substituted pyrrolopyrimidine, pyrazolopyrimidine and purine derivatives and use thereof as lrrk2 inhibitors
JP2018104290A (ja) * 2015-04-28 2018-07-05 アステラス製薬株式会社 ピラジンカルボキサミド化合物を有効成分とする医薬組成物
WO2016173438A1 (zh) * 2015-04-29 2016-11-03 南京明德新药研发股份有限公司 稠环或三环芳基嘧啶化合物用作激酶抑制剂
WO2017011720A1 (en) * 2015-07-16 2017-01-19 Signal Pharmaceuticals, Llc Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CN107949388B (zh) 2015-10-09 2021-10-26 艾森医药公司 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
CN105646496B (zh) * 2016-01-20 2018-07-20 华侨大学 一种7H-吡咯并[2,3-d]嘧啶衍生物、其合成方法及应用
CN107540661A (zh) * 2016-06-24 2018-01-05 正大天晴药业集团股份有限公司 作为egfr抑制剂的苯胺嘧啶化合物的结晶
CN107663208B (zh) * 2016-07-27 2021-10-15 南京圣和药业股份有限公司 一种新型egfr激酶抑制剂的药用盐及其制备方法与用途
CN107663207B (zh) * 2016-07-27 2021-07-30 南京圣和药业股份有限公司 一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法
CN107955019B (zh) * 2016-10-17 2021-09-14 广东众生药业股份有限公司 一种egfr抑制剂的盐型、晶型及其制备方法
CN106749266B (zh) * 2016-11-14 2019-01-22 山东大学 吡咯并[2,3-d]嘧啶类化合物的高效制备方法
CN108299419B (zh) * 2017-01-11 2022-04-26 南京圣和药业股份有限公司 一种新型egfr激酶抑制剂的几种新晶型及其制备方法
JP7164203B2 (ja) 2017-02-08 2022-11-01 中国医▲薬▼研究▲開▼▲発▼中心有限公司 ピロロ芳香族複素環化合物及びその製造方法並びに医薬用途
CN111212837A (zh) * 2017-04-07 2020-05-29 艾森医药公司 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
CN109422751B (zh) * 2017-09-03 2022-04-22 上海美志医药科技有限公司 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
US11709156B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved analytical analysis
US11709155B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
AU2018394997B2 (en) * 2017-12-28 2021-02-04 Daewoong Pharmaceutical Co., Ltd. Oxy-fluoropiperidine derivative as kinase inhibitor
KR102577242B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
WO2019195753A1 (en) 2018-04-05 2019-10-10 Tolero Pharmaceuticals, Inc. Axl kinase inhibitors and use of the same
CA3095580A1 (en) 2018-04-13 2019-10-17 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
CN108530450B (zh) * 2018-05-03 2021-03-30 赖建智 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用
JP2021530554A (ja) 2018-07-26 2021-11-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 異常なａｃｖｒ１発現を伴う疾患を処置するための方法およびそこで使用するためのａｃｖｒ１阻害剤
EP3613738A1 (en) * 2018-08-23 2020-02-26 Lead Discovery Center GmbH 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer
AU2020221247A1 (en) 2019-02-12 2021-08-05 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
CN110407840A (zh) * 2019-08-15 2019-11-05 重庆化工职业学院 一种艾维替尼的制备方法
JP7473642B2 (ja) * 2019-11-13 2024-04-23 ジャージアン・ロングチャーム・バイオ－テック・ファーマ・カンパニー・リミテッド Ｂｔｋ阻害剤としてのピロロピリミジン系化合物およびその使用
US11918936B2 (en) 2020-01-17 2024-03-05 Waters Technologies Corporation Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding
WO2021147952A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN111848631B (zh) * 2020-08-28 2022-04-19 四川大学华西医院 一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN114957248B (zh) * 2022-05-09 2023-12-29 南开大学 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
CN115611989B (zh) * 2022-10-09 2023-08-01 武汉理工大学 机械活化淀粉衍生物抑制剂的优化制备方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563905A (en) 1992-09-24 1996-10-08 Hughes Aircraft Company Network communication system having time-sliced protocol
US7560269B2 (en) 2002-12-20 2009-07-14 Acea Biosciences, Inc. Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays
US7468255B2 (en) 2002-12-20 2008-12-23 Acea Biosciences Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology
US7732127B2 (en) 2002-12-20 2010-06-08 Acea Biosciences, Inc. Dynamic monitoring of cell adhesion and spreading using the RT-CES system
US7470533B2 (en) 2002-12-20 2008-12-30 Acea Biosciences Impedance based devices and methods for use in assays
AU2003267998A1 (en) 2002-07-20 2004-02-09 Acea Biosciences, Inc. Impedance based devices and methods for use in assays
CA2550274A1 (en) 2003-11-12 2005-05-26 Acea Biosciences, Inc. Real time electronic cell sensing systems and applications for cell-based assays
ES2381962T3 (es) * 2005-09-21 2012-06-04 4Sc Ag Nuevos sulfonilpirroles como inhibidores de las HDAC
EP2440559B1 (en) * 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
WO2011079231A1 (en) * 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith

Also Published As

Publication number Publication date
ES2618007T3 (es) 2017-06-20
WO2014025486A1 (en) 2014-02-13
ZA201600648B (en) 2021-09-29
SG11201500872SA (en) 2015-03-30
KR102181365B1 (ko) 2020-11-23
EP2880035B9 (en) 2017-05-17
IN2015DN00914A (el) 2015-06-12
CN103748096B (zh) 2017-10-20
ZA201500762B (en) 2021-09-29
AU2013300106B2 (en) 2017-11-30
MX361992B (es) 2018-12-19
CA2881275C (en) 2020-10-20
JP2017061581A (ja) 2017-03-30
RU2645672C2 (ru) 2018-02-27
BR112015002709B1 (pt) 2022-09-20
CN103748096A (zh) 2014-04-23
MX2015001715A (es) 2015-07-06
DK2880035T3 (en) 2017-03-06
JP6215938B2 (ja) 2017-10-18
KR20150068949A (ko) 2015-06-22
EP3170825B1 (en) 2019-04-10
RU2018104702A (ru) 2019-02-22
AU2013300106A1 (en) 2015-02-19
HUE031955T2 (en) 2017-08-28
LT2880035T (lt) 2017-03-27
NZ629807A (en) 2017-04-28
HRP20170311T1 (hr) 2017-04-21
EP2880035A1 (en) 2015-06-10
BR112015002709A2 (pt) 2017-07-04
PT2880035T (pt) 2017-03-10
CN107266453B (zh) 2020-02-07
CN107266453A (zh) 2017-10-20
RU2015107831A (ru) 2016-09-27
EP2880035B1 (en) 2016-12-07
EP3170825A1 (en) 2017-05-24
CA2881275A1 (en) 2014-02-13
ES2733576T3 (es) 2019-12-02
JP2015524468A (ja) 2015-08-24
HK1210471A1 (en) 2016-04-22

Similar Documents

Publication Publication Date Title
CY1120844T1 (el) Νεες ενωσεις πυρρολοπυριμιδινης ως αναστολεις των πρωτεϊνικων κινασων
MX2018004332A (es) Sales farmaceuticas, formas fisicas y composiciones de inhibidores de pirrolopirimidina cinasa, y metodos para fabricar las mismas.
NZ715687A (en) Pyrimidine derivatives as kinase inhibitors
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1121468T1 (el) Συνδυασμος παραγωγων πυρρολο[2,3-d]πυριμιδινης με εναν ή περισσοτερους επιπροσθετους παραγοντες ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
CY1120734T1 (el) Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6
CY1122611T1 (el) Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης
CY1119588T1 (el) Εκλεκτικοι αναστολεις pi3κ δελτα
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
CY1119714T1 (el) Ενωσεις αναστολεων
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
EA201691930A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-α][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ROS1
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
EA201691484A1 (ru) Соли и твердая форма ингибитора btk
EA201400338A1 (ru) Производные аминопиримидина для применения в качестве модуляторов киназной активности
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
MX347040B (es) Inhibidores de tirosina-cinasas.
MA50375A (fr) Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
DOP2017000209A (es) Derivados de heteroarilo bicíclico fusionados con actividad como inhibidores de phd